Trial Profile
BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms BACHELOR
- 28 Nov 2023 Status changed from recruiting to completed.
- 14 Jan 2022 Planned End Date changed from 1 Oct 2022 to 1 Apr 2024.
- 14 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2023.